Cassava Sciences Inc. (SAVA)
1.38
-0.12 (-8.00%)
At close: Apr 01, 2025, 3:59 PM
1.38
0.36%
After-hours: Apr 01, 2025, 07:59 PM EDT
-8.00% (1D)
| Bid | 1.33 |
| Market Cap | 66.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.38M |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -0.94 |
| Forward PE | -1.92 |
| Analyst | Hold |
| Ask | 1.42 |
| Volume | 1,639,632 |
| Avg. Volume (20D) | 2,092,555 |
| Open | 1.49 |
| Previous Close | 1.50 |
| Day's Range | 1.35 - 1.50 |
| 52-Week Range | 1.35 - 42.20 |
| Beta | -1.24 |
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sci...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2000
Employees 30
Stock Exchange NASDAQ
Ticker Symbol SAVA
Website https://www.cassavasciences.com
Analyst Forecast
According to 3 analyst ratings, the average rating for SAVA stock is "Hold." The 12-month stock price forecast is $54.5, which is an increase of 3863.64% from the latest price.
Stock Forecasts1 week ago
-32.14%
Cassava Sciences shares are trading lower after th...
Unlock content with
Pro Subscription
4 months ago
-10.93%
Cassava Sciences shares are trading lower after HC Wainwright & Co. downgraded the stock from Buy to Neutral and announced a price target of $116.
